Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Avalo Therapeutics Inc AVTX

Healthcare Biotechnology
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1ß mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1ß (IL-1ß... see more

Recent & Breaking News (NDAQ:AVTX)

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

GlobeNewswire April 2, 2024

Avalo Reports 2023 Financial Results and Provides Business Updates

GlobeNewswire March 29, 2024

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

GlobeNewswire March 27, 2024

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

GlobeNewswire December 27, 2023

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

GlobeNewswire December 7, 2023

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

GlobeNewswire November 9, 2023

Avalo Completes Divestiture of AVTX-800 Series

GlobeNewswire October 31, 2023

BestGrowthStocks.com Issues a Comprehensive Analysis of Avalo Therapeutics

TheNewsWire September 27, 2023

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

GlobeNewswire September 26, 2023

Avalo Enters into Agreement to Divest AVTX-800 Series

GlobeNewswire September 12, 2023

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 6, 2023

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

GlobeNewswire August 3, 2023

Avalo to Participate in SVB Securities Therapeutics Forum

GlobeNewswire July 6, 2023

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

GlobeNewswire June 26, 2023

Avalo to Present at the Jefferies Healthcare Conference

GlobeNewswire June 1, 2023

Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board

GlobeNewswire May 22, 2023

Avalo to Present at ATS 2023 Respiratory Innovation Summit

GlobeNewswire May 15, 2023

Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 10, 2023

Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates

GlobeNewswire May 4, 2023

Avalo Reports 2022 Financial Results and Provides Business Updates

GlobeNewswire March 29, 2023